Team:NJU China/Project/Brain

From 2013.igem.org

(Difference between revisions)
 
(62 intermediate revisions not shown)
Line 145: Line 145:
ul#nav {
ul#nav {
-
width:1200px;
+
width:1800px;
-
margin:0 0 0 30px;
+
margin:40px 0 0 30px;
position:relative;
position:relative;
}
}
Line 154: Line 154:
color: #FFFFFF;
color: #FFFFFF;
background-color:none;
background-color:none;
-
margin: 20PX 50px 0 30px;
+
margin: 0 85px 0 0;
float: left;
float: left;
position: relative;
position: relative;
Line 343: Line 343:
body {
body {
-
background: #52be7f;
+
background: #b4e5ff;
color: #fff;
color: #fff;
}
}
Line 401: Line 401:
</head>
</head>
<body>
<body>
-
            <!--Start NavBar-->
+
<div style="float:left; position:absolute; margin-top:-30px; margin-left:-50px; z-index:1; display:block; ">
 +
</br></br>
 +
<a href="https://2013.igem.org"><img src="https://static.igem.org/mediawiki/2013/8/80/NJU-Miniminiminilogocolored.png" ></a>
 +
</div>
 +
<div class="container">
 +
<!--Start NavBar-->
<ul id="nav">  
<ul id="nav">  
     <li><a href="https://2013.igem.org/Team:NJU_China">Home</a></li>
     <li><a href="https://2013.igem.org/Team:NJU_China">Home</a></li>
   
   
-
     <li><a href="https://2013.igem.org/Team:NJU_China/Team">Team</a></li>  
+
     <li><a href="https://2013.igem.org/Team:NJU_China/Project">Project</a>
-
 
+
        <ul>
-
    <li><a href="https://2013.igem.org/Team:NJU_China/Project">Project</a></li>  
+
  <li><a href="https://2013.igem.org/Team:NJU_China/Project">Overview</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Project">Chassis</a></li>  
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Project">Targeting Module</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Project">Killing Module</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Project">Achievement</a></li>
 +
        </ul>
 +
    </li>
 +
    <li><a href="https://2013.igem.org/Team:NJU_China/Modeling">Modeling</a>
 +
    </li>  
-
     <li><a href="https://2013.igem.org/Team:NJU_China/Parts">Parts</a></li>
+
     <li><a href="https://2013.igem.org/Team:NJU_China/Human Practice">Human Practice</a>
 +
        <ul>
 +
  <li><a href="https://2013.igem.org/Team:NJU_China/Human Practice">Free debate</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Human Practice">Reach the unreached</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Human Practice">Workshop</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Human Practice">Collaboration</a></li>
 +
        </ul>
 +
    </li>
-
     <li><a href="https://2013.igem.org/Team:NJU_China/Modeling">Modeling</a></li>  
+
     <li><a href="https://2013.igem.org/Team:NJU_China/Wet lab">Wet lab</a>
 +
        <ul>
 +
  <li><a href="https://2013.igem.org/Team:NJU_China/Protocol">Protocol</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Notebook">Lab notes</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Data Page">Data Page</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Parts">Parts</a></li>
 +
        </ul>
 +
    </li>  
      
      
-
     <li><a href="https://2013.igem.org/Team:NJU_China/Notebook">Notebook</a></li>  
+
     <li><a href="https://2013.igem.org/Team:NJU_China/Safety">Safety</a>
 +
        <ul>
 +
  <li><a href="https://2013.igem.org/Team:NJU_China/Safety">Safety form</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Virus-related_safety">Virus-related safety</a></li>
 +
        </ul>
 +
    </li>  
-
     <li><a href="https://2013.igem.org/Team:NJU_China/Safety">Safety</a></li>
+
     <li><a href="https://2013.igem.org/Team:NJU_China/Team">Team</a></li>
-
     <li><a href="https://2013.igem.org/Team:NJU_China/Attributions">Attributions</a></li>
+
     <li><a href="https://2013.igem.org/Team:NJU_China/Extras">Extras</a>
 +
            <ul>
 +
  <li><a href="https://igem.org/2013_Judging_Form?id=1180">Judging criteria</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Attributions">Attribution</a></li>
 +
          <li><a href="https://2013.igem.org/Team:NJU_China/Acknowledgement">Acknowledgement</a></li>
 +
        </ul>
 +
    </li>
    
    
</ul>
</ul>
-
<!--End NavBar-->  
+
<!--End NavBar-->
-
<div class="container">
+
</br></br></br></br></br>
-
<header>
+
<section>
-
<h1>Liver: <span>For liver targeting, we need to first find a protein specifically recognize hepatic cells. Since Heptitis B virus can infect hepatic cells distinctively, and from recent study[1], we knew that HBV recognizes the hepatic cells via the interaction between the pre-S1 of the HBV envelop protein and NTCP receptor of the hepatic cells. We tried to engineer the pre-S1 from HBV envelope protein to the lamp 2b.
+
<h1>Brain:</h1>
-
Therefore we cloned the pre-S1 into lamp 2b, and we choose pcDNA 3.1(+) as our backbone.</span></h1>
+
<p>
 +
 
 +
For brain targeting, we chose to use RVG, which is a short peptide from Rabies Virus, as our targeting protein. RVG can specifically recognize acetylcholine receptor in the central nervous system [2], thus we engineer the RVG peptide into the lamp 2b and we use pcDNA 3.1(+) as our vector.</br>
 +
To produce the brain-specific RVG exosomes, we first transfected the exosome-producing cells, HEK 293T cells, with the plasmids encoding the fusion protein of lamp 2b and RVG peptide.</br>
 +
Also, we use a siRNA as an indicator to assess the targeting effect of RVG-exosomes and loaded the siRNA into the RVG-modified exosomes by direct transfection of the HEK 293T cells with siRNA probe.
 +
</p></section>
 +
<header>
 +
<h1>
 +
<img src="https://static.igem.org/mediawiki/2013/3/3e/ShibieRVG_small.png">
 +
<img src="https://static.igem.org/mediawiki/2013/a/ae/Pcdna3.1_RVG_small.png">
 +
</h1>
</header>
</header>
-
<div class="component">
 
-
</div>
 
<section>
<section>
-
<p>Site-specific drug delivery has always been a challenge in gene therapy. It is urgently required to develop a new system to overcome the off-target effect, low efficiency and high toxicity of the currently available approaches. Recently, small interfering RNA (siRNA) is emerging as a promising therapeutic drug against a wide array of diseases. Current techniques for siRNA transfer use viruses or synthetic agents as delivery vehicles. However, these approaches are toxic and low-efficient, and more importantly, can not deliver siRNA to specific tissues and organs. </p>
+
<h1>Experimental procedure and Results:</h1>
 +
 
 +
<p>1. Quantification of siRNA contained in the exosomes</BR>
 +
    We first quantify the amount of siRNA encapsulated into the exosomes. siRNA was transfected to the HEK 293T cells(which has already been transfected with RVG-Lamp2b plasmids) before exosome purification. Control group was not transfected with such siRNA.</BR>
 +
    By quantitative PCR analysis of a series of siRNA with known concentration, we drew a standard curve and then use it to calculate the absolute amount of siRNA in the exosomes. As shown in Fig.1, the amount of siRNA in the negative control is quite low (background) while the siRNA contained in the RVG exosomes transfected with siRNA probe reached as high as 0.8 fmol (RNA)/μg (exosome).</br>
 +
The result demonstrates that siRNAs were successfully encapsulated into RVG exosomes.</p>
 +
 
 +
<img width="500px"; height="500px" src="https://static.igem.org/mediawiki/2013/2/20/Njubrain.png">
 +
 
 +
<p>Figure.1 Empty exosome is collected from HEK 293 T cells without transfection of siRNA probe while the RVG exosome +siRNA is collected from the HEK 293T cells after transfection of siRNA probe. The amount of siRNA contained in the exosome is measured by qPCR.</p>
 +
 
 +
<p>2.In vitro evidence for the entry of RVG exosomes into the primary cortical neuron</br>
 +
  To confirm the targeting capability of modified exosomes, we co-culture the siRNA-containing RVG exosomes with primary cortical neurons, and then measure the amounts of siRNA probe in the neurons to see if our RVG exosome can successfully get into the neurons. </br>
 +
From Fig.2, we can see that siRNA probe labeled with Alexaflour 555(red )successfully get into the neurons.</p>
 +
 
 +
<img  src="https://static.igem.org/mediawiki/2013/e/e9/Nju_BRAIN2.png">
 +
<p>Figure.2  Confocal microscopy image of the internalization of Alexaflour 555(red )labeled siRNA into  neurons.</p>
 +
 
 +
<p>In qPCR analysis of the relative siRNA probe level in the neurons co-cultured with both empty RVG-exosomes and siRNA containing RVG-exosomes, respectively (Fig.3), almost no siRNA was detected from the neurons co-cultured with 40 μg empty RVG-exosomes, while the siRNA detected in neurons co-cultured with siRNA probe containing RVG-exosomes show both significant and dose-dependent increase.  </p>
 +
 
 +
<img width="500px"; height="500px" src="https://static.igem.org/mediawiki/2013/5/51/Njubrain3.png">
 +
 
 +
<p>Figure.3 The RNA was extracted from the primary cortical neurons co-cultured 24h with 40 μg empty exosome, 20μg siRNA containing RVG-exosomes,40μg siRNA containing RVG-exosomes, respectively. And the RNA extracted was measured by qPCR using probe for the siRNA encapsulated in the exosomes.</p>
 +
 
 +
<p>3.In vivo evidence for the entry of RVG-exosomes entry into the brain</br>
 +
    To further investigate whether the RVG-exosome can get into brain, we intravenously injected the empty RVG-exosomes, siRNA containing RVG-exosomes, respectively, into the mice. Then we extracted brain tissue and measured the siRNA level in the cortex and medulla.</p>
 +
<p>As shown in Fig.4, no siRNA was detected in both cortex and medulla after the injection of empty RVG-exosomes and siRNA containing exosomes, while for the siRNA containing RVG-exosomes, the siRNA detected in the cortex and medulla are significant higher than the others.</p>
 +
 
 +
<img width="700px"; height="500px" src="https://static.igem.org/mediawiki/2013/c/ce/Njubrain5.png">
 +
 
 +
<p>Figure.4 The mice were intravenously injected with 200 μg empty exosomes,siRNA containing exosomes and siRNA containing RVG-exosomes, respectively once a day, and continued for four days. On the fifth day, the mice were killed and their brains were taken out. The RNA from their cortex and medulla were measured using siRNA probe for the siRNA encapsulated in the exosome.</p>
 +
 
 +
<p>4.In vivo evidence for the targeting effect of RVG-exosome</br>
 +
 
 +
The siRNA contained in the exosomes were designed to silence OPRM gene, which encodesμ- opioid receptor in neuron cells. We intravenously injected three groups of mice: control group is injected with PBS (Mock), second group is injected with empty exosome, third group is injected with RVG-exosome which has siRNA in it. Next, by qPCR analysis we determined the relative OPRM mRNA level in mice brain. The result (Fig.5) shows that RVG exosome successfully target to neuron cells and the siRNA brought by the exosome down-regulate the gene significantly. </p>
-
<p>To better deliver the siRNA and other drugs, we are trying to construct a novel system which employs MVs to encapsulate and protect siRNAs for delivery to target cells. Microvesicles (MVs) are lipid bilayer vesicles which are naturally secreted by almost all cell types, playing crucial roles in intercellular transport of bioactive molecules, including siRNAs. Given the intrinsic ability to traverse biological barriers and to naturally transport functional siRNAs between cells, MVs potentially represent a novel and exciting drug carrier for therapeutic uses. Thus, MVs derived from cells engineered to express siRNAs may be capable of delivering siRNAs to local cellular environment.</p>
+
<img width="700px"; height="500px" src="https://static.igem.org/mediawiki/2013/4/4c/无标题副本.png">
-
<p>To achieve site-specific siRNA delivery, we will express targeting protein onto the surface of MVs and the modified MVs will, in theory, have the ability to target specific tissues and organs. By transfecting the producer cells with siRNA plasmids and collect MVs, we will fill the MVs with therapeutic siRNAs.</p>
+
<p>Figure.5 in vivo evidence for targeting effect of RVG-exosome. First group (Mock) was injected with PBS and second group was injected with Empty exosome. The last group was injected with RVG-exosome which contained siRNA that could silence OPRM gene. The result shows that modified exosome successfully crossed blood-brain-barrier, entered neuron cells and thus significantly silenced OPRM gene.</p>
-
<p>Our modified MVs are just like the “biomissile”, which can be delivered to specific cells and destroy target mRNAs. Our project will open up avenues for therapeutic applications of MVs as biomissile.</p>
+
<p>Finally, with all these data, we demonstrated that our modified exosome can not only cross the blood-brain-barrier but also specifically deliver siRNA to target tissue and thus silence specific gene.</p>
</section>
</section>
</div><!-- /container -->
</div><!-- /container -->

Latest revision as of 01:31, 29 October 2013

<!DOCTYPE html> NJU_China








Brain:

For brain targeting, we chose to use RVG, which is a short peptide from Rabies Virus, as our targeting protein. RVG can specifically recognize acetylcholine receptor in the central nervous system [2], thus we engineer the RVG peptide into the lamp 2b and we use pcDNA 3.1(+) as our vector.
To produce the brain-specific RVG exosomes, we first transfected the exosome-producing cells, HEK 293T cells, with the plasmids encoding the fusion protein of lamp 2b and RVG peptide.
Also, we use a siRNA as an indicator to assess the targeting effect of RVG-exosomes and loaded the siRNA into the RVG-modified exosomes by direct transfection of the HEK 293T cells with siRNA probe.

Experimental procedure and Results:

1. Quantification of siRNA contained in the exosomes
We first quantify the amount of siRNA encapsulated into the exosomes. siRNA was transfected to the HEK 293T cells(which has already been transfected with RVG-Lamp2b plasmids) before exosome purification. Control group was not transfected with such siRNA.
By quantitative PCR analysis of a series of siRNA with known concentration, we drew a standard curve and then use it to calculate the absolute amount of siRNA in the exosomes. As shown in Fig.1, the amount of siRNA in the negative control is quite low (background) while the siRNA contained in the RVG exosomes transfected with siRNA probe reached as high as 0.8 fmol (RNA)/μg (exosome).
The result demonstrates that siRNAs were successfully encapsulated into RVG exosomes.

Figure.1 Empty exosome is collected from HEK 293 T cells without transfection of siRNA probe while the RVG exosome +siRNA is collected from the HEK 293T cells after transfection of siRNA probe. The amount of siRNA contained in the exosome is measured by qPCR.

2.In vitro evidence for the entry of RVG exosomes into the primary cortical neuron
To confirm the targeting capability of modified exosomes, we co-culture the siRNA-containing RVG exosomes with primary cortical neurons, and then measure the amounts of siRNA probe in the neurons to see if our RVG exosome can successfully get into the neurons.
From Fig.2, we can see that siRNA probe labeled with Alexaflour 555(red )successfully get into the neurons.

Figure.2 Confocal microscopy image of the internalization of Alexaflour 555(red )labeled siRNA into neurons.

In qPCR analysis of the relative siRNA probe level in the neurons co-cultured with both empty RVG-exosomes and siRNA containing RVG-exosomes, respectively (Fig.3), almost no siRNA was detected from the neurons co-cultured with 40 μg empty RVG-exosomes, while the siRNA detected in neurons co-cultured with siRNA probe containing RVG-exosomes show both significant and dose-dependent increase.

Figure.3 The RNA was extracted from the primary cortical neurons co-cultured 24h with 40 μg empty exosome, 20μg siRNA containing RVG-exosomes,40μg siRNA containing RVG-exosomes, respectively. And the RNA extracted was measured by qPCR using probe for the siRNA encapsulated in the exosomes.

3.In vivo evidence for the entry of RVG-exosomes entry into the brain
To further investigate whether the RVG-exosome can get into brain, we intravenously injected the empty RVG-exosomes, siRNA containing RVG-exosomes, respectively, into the mice. Then we extracted brain tissue and measured the siRNA level in the cortex and medulla.

As shown in Fig.4, no siRNA was detected in both cortex and medulla after the injection of empty RVG-exosomes and siRNA containing exosomes, while for the siRNA containing RVG-exosomes, the siRNA detected in the cortex and medulla are significant higher than the others.

Figure.4 The mice were intravenously injected with 200 μg empty exosomes,siRNA containing exosomes and siRNA containing RVG-exosomes, respectively once a day, and continued for four days. On the fifth day, the mice were killed and their brains were taken out. The RNA from their cortex and medulla were measured using siRNA probe for the siRNA encapsulated in the exosome.

4.In vivo evidence for the targeting effect of RVG-exosome
The siRNA contained in the exosomes were designed to silence OPRM gene, which encodesμ- opioid receptor in neuron cells. We intravenously injected three groups of mice: control group is injected with PBS (Mock), second group is injected with empty exosome, third group is injected with RVG-exosome which has siRNA in it. Next, by qPCR analysis we determined the relative OPRM mRNA level in mice brain. The result (Fig.5) shows that RVG exosome successfully target to neuron cells and the siRNA brought by the exosome down-regulate the gene significantly.

Figure.5 in vivo evidence for targeting effect of RVG-exosome. First group (Mock) was injected with PBS and second group was injected with Empty exosome. The last group was injected with RVG-exosome which contained siRNA that could silence OPRM gene. The result shows that modified exosome successfully crossed blood-brain-barrier, entered neuron cells and thus significantly silenced OPRM gene.

Finally, with all these data, we demonstrated that our modified exosome can not only cross the blood-brain-barrier but also specifically deliver siRNA to target tissue and thus silence specific gene.